Karp S J, Young T E, Bakowski M T, Spittle M F
J R Soc Med. 1986 Oct;79(10):588-92. doi: 10.1177/014107688607901010.
Thirteen patients were entered into an uncontrolled pilot study to investigate the response to, and toxicity of, a combination of cisplatinum (20 mg/m2) and bleomycin (6 mg/m2) infused daily for 5 days and repeated every 21 days up to a maximum of 4 cycles, in the treatment of squamous cell carcinoma of the bronchus. This regimen was subsequently followed by a split course of local irradiation. All patients have been followed to death. Six patients showed a partial response to chemotherapy while 7 showed no response or progressive disease. The median survival was 5 months. The median survival of the responders was 15 months and that of the nonresponders 3 months. Two patients developed the syndrome of inappropriate antidiuretic hormone secretion from which one died. The longest survivor, who died 26 months after the commencement of chemotherapy, had severe mediastinal and pulmonary fibrosis.
13名患者进入一项非对照的初步研究,以调查顺铂(20mg/m²)和博来霉素(6mg/m²)联合用药的疗效和毒性,该联合用药方案为每日输注,持续5天,每21天重复一次,最多进行4个周期,用于治疗支气管鳞状细胞癌。该方案随后进行了局部照射的分割疗程。所有患者均随访至死亡。6名患者对化疗有部分反应,而7名患者无反应或疾病进展。中位生存期为5个月。有反应者的中位生存期为15个月,无反应者为3个月。2名患者出现抗利尿激素分泌不当综合征,其中1例死亡。最长生存期的患者在化疗开始后26个月死亡,患有严重的纵隔和肺纤维化。